1,4-Bis(1-naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance

Oncology Reports

Volumn 12, Issue 1, 2004, Pages 91-96

  Novi, Marino ^a   Ottone, Massimo ^b   Dell'Erba, Carlo ^a   Barbieri, Federica ^b   Chiavarina, Barbara ^b   Maccagno, Massimo ^a   Viale, Maurizio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

1,4 bis(1 naphthyl) 2,3 dinitro 1,3 butadiene; Drug resistance; Mechanisms of resistance

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 BIS(1 NAPHTHYL) 2,3 DINITRO 1,3 BUTADIENE; 1,4-BIS(1-NAPHTHYL)-2,3-DINITRO-1,3-BUTADIENE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ARTICLE; CELL DIVISION; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; KINETICS; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BUTADIENES; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; KINETICS; PACLITAXEL;

EID: 10244275837     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.1.91     Document Type: Article

References (26)

1. Dell'Erba C, Mele A, Novi M, Petrillo G and Stagnaro P: Synthetic exploitation of the ring-opening of 3,4-dinitrothiophene. Access to 1,4-disubstituted 2,3-dinitro-l,3-butadienes and 2,3-butanedione dioximes. Tetrahedron 48: 4407-4418, 1992.
2. Bianchi L, Dell'Erba C, Gabellini A, Novi M, Petrillo G and Tavani C: Access to 3-arylmethyl-5-(methylthio)isoxazoles via an initial ring-opening of 2-methylthio-4-nitrothiophene. Tetrahedron 58: 3379-3385, 2002. (Pubitemid 34415520)
3. Viale M, Ottone M, Chiavarina B, Mariggiö MA, Prevosto C, Dell'Erba C, Petrillo G and Novi M: Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by l,4-bis(l-naphthyl)-2,3-dinitro-l,3- butadiene. Invest New Drug (In press).
4. Hussain RF, Nouri AME and Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89-96, 1993.
5. Rowe TC, Chen GL, Hsiang YH and Liu LF: DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46: 2021-2026, 1986. (Pubitemid 16117901)
6. Morrow CS and Cowan KH: Drug resistance and its clinical circumvention. In: Cancer Medicine. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E and Gansler TS (eds). 5th edition, Becker BC Inc. Publisher, Hamilton, pp539-555, 2000.
7. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
8. Kavallaris M, Kuo DYS, Burkhart CA, Regi DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997. (Pubitemid 27386315)
9. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman M and Benard J: Expression of a human multidrug resistance gene in ovarian carcinoma. Cancer Res 49: 5062-5065, 1989. (Pubitemid 19239344)
10. Kartalou M and Essigmann JM: Mechanisms of cisplatin resistance. Mutat Res 478: 23-43, 2001.
11. Guglielmi A, Aschele C, Grossi F, Tixi L and Sobrero A: Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer. Cytotechnology 19: 215-219, 1996. (Pubitemid 26324495)
12. Richon VM, Schulte N and Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47: 2056-2061, 1987. (Pubitemid 17074608)
13. Viale M, Cafaggi S, Parodi B and Esposito M: Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine 1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 35: 371-376, 1995.
14. Alaoui Jamali MA, Yin MB, Mazzoni A, Bankusli I and Rustum YM: Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933. Cancer Chemother Pharmacol 25: 77-83, 1989. (Pubitemid 20009431)
15. Barbieri F, Alama A, Tasso B, Boido V, Bruzzo C and Sparatore F: Quinolizidinyl derivatives of iminodibenzyl and phenotiazine as multidrug resistance modulators in ovarian cancer cells. Invest New Drug 21: 413-420, 2003. (Pubitemid 38124980)
16. Aschele C, Sobrero A, Faderan MA and Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864, 1992.
17. Lockshin A and Danemberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30: 247-257, 1981. (Pubitemid 11210738)
18. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L and Jordan MA: Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl AcadSci USA 98: 11737-11741, 2001. (Pubitemid 32928798)
19. Ling V: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40: S3-S8, 1997.
20. Cullinane C, Cutts SM, Panousis C and Phillips DR: Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acid Res 28: 1019-1025, 2000. (Pubitemid 30085330)
21. Skladanowski A and Konopa J: Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumours cells. Br J Cancer 82: 1300-1304,2000. (Pubitemid 30145349)
22. Macdonald JS: Advances in the therapy of gastric cancer. Gastric Cancer 5 (Suppl 1): 35-40, 2002.
23. Rao S and Cunningham D: Adjuvant therapy for colon cancer in the new millenium. Scand J Surg 92: 57-64, 2003. (Pubitemid 36406637)
24. Oettle H and Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 95 (Suppl 4): 912-922, 2003.
25. Gustin DM and Brenner DE: Chemoprevention of colon cancer: current status and future prospects. Cancer Metastasis Rev 21: 323-348, 2002. (Pubitemid 36071919)
26. McCormick D, Kibbe PJ and Morgan SW: Colon cancer: prevention, diagnosis, treatment. Gastroenterol Nurs 25: 204-211, 2002.